SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has
been included in the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly
(ADP-ribose)